Literature DB >> 30208338

Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?

Estelle Ayme-Dietrich1, Roland Lawson1, Sylvia Da-Silva1, Jean Philippe Mazzucotelli2, Laurent Monassier3.   

Abstract

Heart valve disease (HVD) is a complex entity made by different pathological processes that ultimately lead to the abnormal structure and disorganization of extracellular matrix proteins resulting to dysfunction of the leaflets. At its final evolutionary step, treatments are limited to the percutaneous or surgical valve replacement, whatever the original cause of the degeneration. Understanding early molecular mechanisms that regulate valve interstitial cells remodeling and disease progression is challenging and could pave the way for future drugs aiming to prevent and/or reverse the process. Some valve degenerative processes such as the carcinoid heart disease, drug-induced valvulopathy and degenerative mitral valve disease in small-breed dogs are clearly linked to serotonin. The carcinoid heart is typically characterized by a right-sided valve dysfunction, observed in patients with carcinoid tumors developed from serotonin-producing gut enterochromaffin cells. Fenfluramine or ergot derivatives were linked to mitral and aortic valve dysfunction and share in common the pharmacological property of being 5-HT2B receptor agonists. Finally, some small-breed dogs, such as the Cavalier King Charles Spaniel are highly prone to degenerative mitral valve disease with a prevalence of 40% at 4 years-old, 70% at 7 years-old and 100% in 10-year-old animals. This degeneration has been linked to high serum serotonin, 5-HT2B receptor overexpression and SERT downregulation. Through the comprehension of serotonergic mechanisms involved into these specific situations, new therapeutic approaches could be extended to HVD in general. More recently, a serotonin dependent/ receptor independent mechanism has been suggested in congenital mitral valve prolapse through the filamin-A serotonylation. This review summarizes clinical and molecular mechanisms linking the serotonergic system and heart valve disease, opening the way for future pharmacological research in the field.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac valve lesions; Remodeling; Serotonin; Valvulopathy

Mesh:

Substances:

Year:  2018        PMID: 30208338     DOI: 10.1016/j.phrs.2018.09.009

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  7 in total

1.  Methamphetamine-induced lethal toxicity in zebrafish larvae.

Authors:  Yu Chen; Alexander S Wisner; Isaac T Schiefer; Frederick E Williams; F Scott Hall
Journal:  Psychopharmacology (Berl)       Date:  2022-10-21       Impact factor: 4.415

Review 2.  Update in carcinoid heart disease - the heart of the matter.

Authors:  Kira Oleinikov; Amit Korach; David Planer; Dan Gilon; Simona Grozinsky-Glasberg
Journal:  Rev Endocr Metab Disord       Date:  2021-01-14       Impact factor: 9.306

3.  Polymorphisms in the serotonin transporter gene and circulating concentrations of neurotransmitters in Cavalier King Charles Spaniels with myxomatous mitral valve disease.

Authors:  Maria J Reimann; Merete Fredholm; Signe E Cremer; Liselotte B Christiansen; Kathryn M Meurs; Jacob E Møller; Jens Häggström; Jens Lykkesfeldt; Lisbeth H Olsen
Journal:  J Vet Intern Med       Date:  2021-10-02       Impact factor: 3.333

Review 4.  Serotonin-A Driver of Progressive Heart Valve Disease.

Authors:  Helge Waldum; Alexander Wahba
Journal:  Front Cardiovasc Med       Date:  2022-01-28

5.  Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.

Authors:  Carla Pallavicini; Enzo Tagliazucchi; Federico Cavanna; Stephanie Muller; Laura Alethia de la Fuente; Federico Zamberlan; Matías Palmucci; Lucie Janeckova; Martin Kuchar
Journal:  Transl Psychiatry       Date:  2022-08-02       Impact factor: 7.989

Review 6.  Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy.

Authors:  Debopam Samanta
Journal:  Children (Basel)       Date:  2022-08-02

Review 7.  Serotonin: a platelet hormone modulating cardiovascular disease.

Authors:  Marina Rieder; Nadine Gauchel; Christoph Bode; Daniel Duerschmied
Journal:  J Thromb Thrombolysis       Date:  2020-11-05       Impact factor: 2.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.